{"gene":"TNFSF10","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":1997,"finding":"TRAIL (TNFSF10) binds to DR4 (death receptor-4), an undescribed TNF-receptor family member containing a cytoplasmic death domain that engages the cell apoptotic apparatus. DR4 could not use FADD to transmit the death signal, unlike Fas, TNFR-1, and DR3, indicating distinct proximal signaling machinery.","method":"Receptor identification via homology/database searching, functional death domain characterization, FADD signaling assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — foundational receptor identification with functional characterization, widely replicated across the field","pmids":["9082980"],"is_preprint":false},{"year":1997,"finding":"TRAIL binds a second distinct receptor, TRAIL-R2, identified by ligand-based affinity purification. TRAIL-R2 contains two extracellular cysteine-rich repeats and a cytoplasmic death domain, mediates caspase-dependent apoptosis, and uses the intracellular adaptor molecule FADD/MORT1 (in contrast to TRAIL-R1).","method":"Ligand-based affinity purification, molecular cloning, TRAIL-R2-Fc fusion protein inhibition assay, FADD interaction characterization","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution via affinity purification, cloning, functional inhibition assay, replicated across labs","pmids":["9311998"],"is_preprint":false},{"year":2008,"finding":"TRAIL (TNFSF10) is a transcriptional target of p53. Two p53 DNA-binding sites exist in the human TNFSF10 promoter at 346 and 625 bp upstream of the transcription start site. Ad-p53 induced TRAIL mRNA and protein in HCT116 p53-/- cells; TRAIL promoter reporter assay confirmed p53-dependent transactivation. siRNA knockdown of TNFSF10 suppressed caspase-3/7 activity after adriamycin treatment.","method":"Adenoviral p53 overexpression, TRAIL promoter-luciferase reporter assay, siRNA knockdown, caspase activity assay","journal":"Cancer biology & therapy","confidence":"High","confidence_rationale":"Tier 1 / Moderate — promoter reporter assay with defined binding sites, loss-of-function siRNA, multiple orthogonal methods in one study","pmids":["19106633"],"is_preprint":false},{"year":2012,"finding":"TRAIL-induced autophagy is cytoprotective and attenuates TRAIL-induced apoptosis. The mechanism involves TRAF2- and RIPK1-mediated MAPK8/JNK activation, which promotes BCL2L1/Bcl-xL degradation and dissolution of the BCL2L1-BECN1 complex. MAPK8 blockade, but not NFκB blockade, inhibited TRAIL-induced autophagy; knockdown of TRAF2 or RIPK1 suppressed MAPK8 activation and autophagy. Suppressing autophagy increased TRAIL DISC formation.","method":"Pharmacological inhibitors, siRNA knockdown of BECN1, ATG7, TRAF2, RIPK1, MAPK8; DISC formation assay; Western blot","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal siRNA and pharmacological interventions, DISC formation readout, single lab","pmids":["23051914"],"is_preprint":false},{"year":2009,"finding":"PRMT5 (protein arginine methyltransferase 5) is a novel TRAIL receptor-binding protein that selectively interacts with DR4 and DR5 but not with TNFR1 or Fas. PRMT5 promotes TRAIL-induced IKK and NF-κB activation, contributing to TRAIL resistance. PRMT5 gene silencing sensitized cancer cells to TRAIL without affecting TRAIL resistance in nontransformed cells; this sensitization was rescued by ectopic active IKKβ.","method":"Proteomic screening, Co-immunoprecipitation, siRNA knockdown, IKK/NF-κB activity assay, ectopic IKKβ rescue","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal interaction confirmed by proteomic screen and Co-IP, functional rescue experiment, single lab","pmids":["19372584"],"is_preprint":false},{"year":2014,"finding":"TRAF2 is a negative regulator of TRAIL-induced apoptosis and necroptosis. TRAF2 knockdown sensitized keratinocytes and HeLa cells to TRAIL-induced caspase-dependent apoptosis; in RIP3-expressing cells, TRAF2 KD additionally sensitized cells to TRAIL-induced necroptosis. TRAIL-induced necroptosis did not depend on autocrine TNF/TNFR signaling.","method":"siRNA knockdown of TRAF2, pan-caspase inhibition (zVAD-fmk), RIP1 inhibitor (necrostatin-1), RIP3-transfected HeLa cells, TWEAK priming to deplete cytosolic TRAF2, TNFR2-Fc/anti-TNFα blocking","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple cell models, pharmacological + genetic perturbations, orthogonal inhibitors confirming both apoptotic and necroptotic roles","pmids":["25299769"],"is_preprint":false},{"year":2015,"finding":"PARP1-mediated poly-ADP-ribosylation of HMGB1 is required for TRAIL-induced HMGB1 cytoplasmic translocation and subsequent HMGB1-BECN1 complex formation, which drives cytoprotective autophagy and TRAIL resistance. Pharmacological PARP1 inhibition or PARP1 knockdown suppressed TRAIL-induced HMGB1 translocation, reduced autophagy, increased apoptosis, and enhanced TRAIL anticancer activity.","method":"PARP1 inhibitors, siRNA knockdown of PARP1, HMGB1 localization assay, Co-immunoprecipitation of HMGB1-BECN1, in vitro and in vivo (subcutaneous tumor) models","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, genetic and pharmacological inhibition, in vivo validation, single lab","pmids":["25607248"],"is_preprint":false},{"year":2005,"finding":"TRAIL-R1-selective and TRAIL-R2-selective mutants of TRAIL were synthesized. Primary CLL and mantle cell lymphoma cells signal apoptosis almost exclusively through TRAIL-R1, demonstrated by selective receptor binding and DISC formation assays using receptor-specific TRAIL mutants.","method":"Synthesis of receptor-selective TRAIL mutants, selective receptor binding assay, DISC formation assay, primary patient cell apoptosis assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — receptor-selective mutants with direct binding and DISC formation validation, primary patient cells, multiple methods","pmids":["16357130"],"is_preprint":false},{"year":2017,"finding":"N-linked glycosylation of TRAIL-R1 (and mouse TRAIL-R) promotes TRAIL-induced apoptosis by enhancing receptor aggregation and DISC formation, but does not affect TRAIL-binding affinity. N-glyc-deficient mutants of TRAIL-R1 showed reduced apoptotic signaling, lower receptor aggregation, and reduced DISC formation. Additionally, N-glycosylation of TRAIL-R1 reduces binding affinity for CMV UL141 protein, which restricts TRAIL-R1 surface expression.","method":"N-glycosylation-defective mutagenesis, apoptosis assays, DISC formation assay, receptor aggregation analysis, TRAIL binding affinity measurement, UL141 binding affinity assay","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis with multiple functional readouts (DISC, aggregation, binding, viral evasion), single lab with orthogonal methods","pmids":["28186505"],"is_preprint":false},{"year":2014,"finding":"Concomitant binding of non-tagged Apo2L/TRAIL and the TRAIL-R2-specific antibody AMG655 to TRAIL-R2 synergistically enhances DISC formation and cancer cell killing. The increased killing was due to enhanced TRAIL-R2 DISC formation enabled by simultaneous ligand and antibody engagement.","method":"DISC formation assay, apoptosis assay in cancer cell lines and primary ovarian cancer cells, combination treatment with non-tagged TRAIL + AMG655","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — DISC formation mechanistic assay, validated in primary cells, single lab with two orthogonal methods","pmids":["24909167"],"is_preprint":false},{"year":2021,"finding":"TRAIL expression in astrocytes (LAMP1+TRAIL+ subset) is driven by IFNγ produced by meningeal NK cells (which are licensed by the gut microbiome). These astrocytes limit CNS inflammation by inducing T cell apoptosis via TRAIL-DR5 signaling. TRAIL expression in astrocytes is repressed by molecules from T cells and microglia during inflammation.","method":"High-throughput flow cytometry screening, single-cell RNA sequencing, CRISPR-Cas9-based cell-specific in vivo genetic perturbations in mice, T cell apoptosis assay","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR-Cas9 genetic perturbation in vivo, multiple orthogonal methods, published in high-tier journal with rigorous validation","pmids":["33408417"],"is_preprint":false},{"year":2016,"finding":"Hepatitis B virus X protein (HBx) promotes autophagy-mediated lysosomal degradation of TRAIL death receptor TNFRSF10B/DR5, restricting TRAIL-induced apoptosis in virus-infected hepatocytes. HBx directly interacts with TNFRSF10B and recruits it to phagophores via an autophagy receptor-like mechanism, promoting association of TNFRSF10B with LC3B.","method":"Immunoprecipitation, GST affinity isolation, LC3B knockdown, pharmacological autophagy inhibition, tandem-fluorescence-tagged LC3B microscopy, immunoblotting of patient liver tissues","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 1 / Moderate — GST pulldown and Co-IP, genetic and pharmacological autophagy inhibition, patient tissue validation, multiple orthogonal methods","pmids":["27740879"],"is_preprint":false},{"year":2021,"finding":"TRAIL signaling activates entosis (cell-in-cell formation) in colon cancer cells via DR4 and DR5 receptors. Entosis induction diverges from apoptosis at caspase-8: structural presence of caspase-8 is sufficient for entosis but not apoptosis. Bax/Bak knockout or caspase inhibition also inhibits entotic cell death. CIC structures in colorectal tumors associate with TRAIL signaling and adverse prognosis.","method":"TRAIL receptor KO (DR4/DR5), caspase-8 structural mutants, Bax/Bak double knockout, caspase inhibition, live imaging, colorectal tumor analysis","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO of receptors and downstream components, structural mutant rescue, mechanistic bifurcation between apoptosis and entosis established","pmids":["34546352"],"is_preprint":false},{"year":2003,"finding":"In rhabdomyosarcoma cells, TRAIL ligation induces DISC formation with recruitment of FADD and procaspase-8 in both sensitive and resistant cells. TRAIL-induced apoptosis has a caspase-8-independent component: dominant-negative caspase-8 only partially inhibited TRAIL-induced apoptosis and did not inhibit Bid cleavage or Bax activation, while dominant-negative FADD completely abolished TRAIL-induced cell death. Inhibition of sphingosine kinase completely protected cells from TRAIL-induced apoptosis, implicating the sphingomyelin cycle.","method":"DISC formation assay, dominant-negative FADD/caspase-8 overexpression, Bcl-2/Bcl-xL overexpression, Bax activation assay, sphingosine kinase inhibition","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dominant-negative constructs and rescue experiments, DISC assay, multiple pathway dissection methods, single lab","pmids":["12761581"],"is_preprint":false},{"year":2016,"finding":"TRAIL-mediated necroptosis requires acid and neutral sphingomyelinases, mitochondrial serine protease HtrA2/Omi, Atg5, and vacuolar H(+)-ATPase, and is independent of PARP-1. TRAIL-mediated necroptosis differs from TNF-mediated necroptosis in not requiring UCH-L1 or Atg16L1, and does not require receptor internalization or endosome-lysosome acidification. Bcl-XL overexpression inhibited TRAIL- but not TNF-mediated necroptosis in Colo357 cells.","method":"Pharmacological inhibitors, genetic knockdown, Bcl-2/Bcl-XL overexpression, receptor internalization assay, endosome acidification inhibition","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological and genetic perturbations, comparative TNF vs TRAIL necroptosis, single lab","pmids":["27528614"],"is_preprint":false},{"year":2004,"finding":"TRAIL expression in megakaryocytes is induced upon megakaryocytic differentiation via increased transcriptional activity of the TRAIL promoter, indicating lineage-specific transcriptional regulation. Activated platelets express both membrane-bound and soluble TRAIL, synthesized during megakaryocyte differentiation.","method":"Immunoprecipitation, ELISA, flow cytometry, RT-PCR, TRAIL promoter/reporter transient transfection assays, TRAIL-dependent cytotoxicity assays","journal":"Experimental hematology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter assay with multiple protein-level validations, single lab","pmids":["15539085"],"is_preprint":false},{"year":2005,"finding":"During human megakaryocytic development, surface TRAIL and TRAIL-R2 are co-expressed starting from early differentiation. Recombinant TRAIL increases apoptosis of CD34+/CD41(dim) megakaryoblasts and decreases total megakaryocytic output. Blockade of endogenous TRAIL-TRAIL-R2 interaction by TRAIL-R2-Fc chimera increases total megakaryocytic cell count, demonstrating an autocrine/paracrine regulatory role of endogenous TRAIL in megakaryocytopoiesis.","method":"Flow cytometry of surface receptors, recombinant TRAIL treatment, TRAIL-R2-Fc chimera blockade, primary CD34+ cell culture differentiation assay","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional ligand-receptor blockade with defined cellular readout, primary human cells, single lab","pmids":["15828026"],"is_preprint":false},{"year":1999,"finding":"TRAIL and all four TRAIL receptors (DR4, DR5, DcR1, DcR2) are expressed in human placentas by Northern blotting. TRAIL protein is prominent in syncytiotrophoblast and Hofbauer cells by immunohistochemistry. Trophoblast cell lines are resistant to rTRAIL killing while macrophage lines are partially susceptible. IFN-γ increases TRAIL mRNA in both lineages but only increases DR4 mRNA in macrophages. These findings support a role for the TRAIL/TRAIL-R system in placental immune privilege.","method":"Northern blotting, immunohistochemistry, cytotoxicity assays, IFN-γ stimulation, cell lineage-specific receptor expression analysis","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (Northern, IHC, functional cytotoxicity), primary tissue and cell lines, single lab","pmids":["10229846"],"is_preprint":false}],"current_model":"TNFSF10/TRAIL is a TNF superfamily member that, as a trimer, binds death receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2)—each containing cytoplasmic death domains—to recruit FADD and procaspase-8 into a death-inducing signaling complex (DISC), initiating caspase-dependent apoptosis; DR4 signals independently of FADD while DR5 uses FADD/MORT1, TRAIL-R1 is regulated by N-linked glycosylation that promotes DISC formation, TRAIL expression is transactivated by p53 and by IFNγ in immune cells including NK cells and astrocytes, and non-apoptotic TRAIL outcomes (NF-κB activation, autophagy, entosis, necroptosis) are modulated by TRAF2, RIPK1/MAPK8, PARP1-HMGB1, PRMT5, and receptor compartmentalization."},"narrative":{"mechanistic_narrative":"TNFSF10 (TRAIL) is a TNF-superfamily death ligand that engages cell-surface death receptors to trigger caspase-dependent apoptosis and a broader set of regulated cell-death and inflammatory programs [PMID:9082980, PMID:9311998]. It binds two distinct death-domain-containing receptors: DR4/TRAIL-R1, which initially appeared to transmit death signals through machinery distinct from FADD, and TRAIL-R2/DR5, which recruits the adaptor FADD/MORT1 to assemble a death-inducing signaling complex (DISC) with procaspase-8 [PMID:9082980, PMID:9311998, PMID:12761581]. DISC assembly and apoptotic output are tunable: N-linked glycosylation of TRAIL-R1 enhances receptor aggregation and DISC formation without altering ligand affinity [PMID:28186505], receptor-selective TRAIL variants reveal that some primary tumors signal almost exclusively through TRAIL-R1 [PMID:16357130], and co-engagement of TRAIL-R2 by ligand plus the agonist antibody AMG655 synergistically amplifies DISC formation and killing [PMID:24909167]. TRAIL also drives non-apoptotic outcomes through the same receptors—cytoprotective autophagy via TRAF2/RIPK1-MAPK8/JNK signaling that degrades BCL2L1 and via PARP1-dependent HMGB1-BECN1 complex formation [PMID:23051914, PMID:25607248], necroptosis dependent on sphingomyelinases and HtrA2/Omi [PMID:25299769, PMID:27528614], and entosis that diverges from apoptosis at caspase-8 [PMID:34546352]—with TRAF2 and PRMT5 acting as negative regulators that restrain death signaling and promote NF-κB-driven resistance [PMID:19372584, PMID:25299769]. TRAIL expression is transcriptionally controlled: it is a direct p53 target gene through promoter binding sites that mediate chemotherapy-induced apoptosis [PMID:19106633], and is induced by IFNγ in immune and tissue contexts, including IFNγ-driven astrocytes that limit CNS inflammation by inducing T-cell apoptosis through TRAIL-DR5 [PMID:33408417]. Lineage-specific induction also governs roles in megakaryocyte differentiation, where autocrine TRAIL-TRAIL-R2 signaling regulates megakaryocytic output [PMID:15539085, PMID:15828026].","teleology":[{"year":1997,"claim":"Establishing the receptors through which TRAIL signals defined how an extracellular ligand engages the intracellular apoptotic apparatus, and revealed early evidence for receptor-specific signaling logic.","evidence":"Receptor identification by homology/database searching and ligand-based affinity purification, with death-domain and FADD-signaling characterization (DR4/TRAIL-R1 and TRAIL-R2/DR5)","pmids":["9082980","9311998"],"confidence":"High","gaps":["The apparent FADD-independence of DR4 versus FADD-dependence of DR5 was not reconciled at the structural level","Stoichiometry of the receptor-FADD-procaspase-8 DISC was not resolved"]},{"year":2003,"claim":"Dissecting DISC composition in sensitive versus resistant cells showed apoptotic output is not strictly caspase-8-dependent, implicating parallel pathways including sphingolipid signaling.","evidence":"DISC assay with dominant-negative FADD/caspase-8 overexpression, Bax activation assay, and sphingosine kinase inhibition in rhabdomyosarcoma cells","pmids":["12761581"],"confidence":"Medium","gaps":["The molecular identity of the caspase-8-independent death effector was not established","Single-lab, single-tumor-type observation"]},{"year":2005,"claim":"Receptor-selective TRAIL mutants demonstrated that individual tumors can depend on a single receptor, with direct therapeutic targeting implications.","evidence":"Synthesis of TRAIL-R1- and TRAIL-R2-selective mutants with selective binding and DISC formation assays in primary CLL and mantle cell lymphoma cells","pmids":["16357130"],"confidence":"High","gaps":["Why these tumors favor TRAIL-R1 was not mechanistically explained","Receptor preference across broader tumor types was not surveyed"]},{"year":2008,"claim":"Identifying TNFSF10 as a direct p53 target connected the apoptotic ligand to the canonical tumor-suppressor and chemotherapy response.","evidence":"Adenoviral p53 overexpression, TRAIL promoter-luciferase reporter with mapped binding sites, siRNA knockdown, and caspase activity assays in HCT116 cells","pmids":["19106633"],"confidence":"High","gaps":["The relative contribution of p53-driven TRAIL versus other p53 apoptotic targets was not quantified","In vivo relevance to tumor regression was not tested here"]},{"year":2009,"claim":"Discovery of PRMT5 as a selective death-receptor-binding protein revealed a built-in resistance mechanism coupling receptor engagement to NF-κB survival signaling.","evidence":"Proteomic screen, Co-IP showing selective DR4/DR5 (not TNFR1/Fas) binding, siRNA knockdown, and IKKβ rescue of NF-κB activity","pmids":["19372584"],"confidence":"Medium","gaps":["Whether PRMT5 methyltransferase activity is required was not resolved","Structural basis of selective receptor binding unknown","Single-lab finding"]},{"year":2012,"claim":"Mapping a TRAF2/RIPK1-MAPK8 axis showed TRAIL induces cytoprotective autophagy that antagonizes its own DISC formation, explaining a source of resistance.","evidence":"Pharmacological inhibitors and siRNA knockdown of TRAF2, RIPK1, MAPK8, BECN1, ATG7 with DISC formation readout","pmids":["23051914"],"confidence":"High","gaps":["How autophagy physically suppresses DISC assembly was not defined","Single-lab finding"]},{"year":2014,"claim":"TRAF2 was established as a negative regulator gating both apoptosis and RIP3-dependent necroptosis downstream of TRAIL, independent of autocrine TNF.","evidence":"siRNA knockdown of TRAF2 with zVAD-fmk, necrostatin-1, RIP3 transfection, and TNF blockade across keratinocytes and HeLa cells","pmids":["25299769"],"confidence":"High","gaps":["The biochemical target through which TRAF2 restrains the DISC was not identified","Generality across cell types not fully mapped"]},{"year":2014,"claim":"Combining TRAIL with an agonist TRAIL-R2 antibody showed DISC formation can be cooperatively amplified, providing a route to overcome resistance.","evidence":"DISC formation and apoptosis assays with non-tagged Apo2L/TRAIL plus AMG655 in cancer cell lines and primary ovarian cancer cells","pmids":["24909167"],"confidence":"Medium","gaps":["The receptor cluster geometry enabling synergy was not structurally defined","Single-lab finding"]},{"year":2015,"claim":"A PARP1-HMGB1 axis was shown to drive cytoprotective autophagy and TRAIL resistance, identifying a distinct druggable resistance node.","evidence":"PARP1 inhibitors and knockdown, HMGB1 localization, HMGB1-BECN1 Co-IP, and subcutaneous tumor models","pmids":["25607248"],"confidence":"Medium","gaps":["How PARP1 is activated by TRAIL signaling was not established","Relationship to the TRAF2/RIPK1 autophagy axis not integrated","Single-lab finding"]},{"year":2016,"claim":"Defining the effector requirements of TRAIL-mediated necroptosis distinguished it mechanistically from TNF necroptosis.","evidence":"Pharmacological and genetic perturbation of sphingomyelinases, HtrA2/Omi, Atg5, V-ATPase; receptor internalization and endosome acidification assays in Colo357 cells","pmids":["27528614"],"confidence":"Medium","gaps":["How these effectors are assembled into a death-executing module was not resolved","Single-lab finding"]},{"year":2016,"claim":"Hepatitis B virus X protein was shown to degrade DR5 via selective autophagy, demonstrating viral subversion of TRAIL death signaling.","evidence":"Co-IP, GST pulldown, LC3B knockdown, autophagy inhibition, tandem-fluorescent LC3B imaging, and patient liver tissue immunoblotting","pmids":["27740879"],"confidence":"High","gaps":["Whether host autophagy receptors normally turn over DR5 was not addressed","Generality beyond HBV-infected hepatocytes unknown"]},{"year":2017,"claim":"N-linked glycosylation of TRAIL-R1 was shown to control apoptotic competence by promoting receptor aggregation and DISC formation independent of ligand affinity, and to mediate viral immune evasion.","evidence":"N-glycosylation-defective mutagenesis with apoptosis, DISC, receptor aggregation, ligand affinity, and CMV UL141 binding assays","pmids":["28186505"],"confidence":"High","gaps":["How glycosylation status varies across cell types to set sensitivity was not surveyed","Structural basis of glycan-driven aggregation not resolved"]},{"year":2021,"claim":"TRAIL signaling was shown to trigger entosis as a caspase-8-gated alternative to apoptosis, expanding the death-modality repertoire and linking it to tumor prognosis.","evidence":"DR4/DR5 KO, caspase-8 structural mutants, Bax/Bak double KO, caspase inhibition, live imaging, and colorectal tumor analysis","pmids":["34546352"],"confidence":"High","gaps":["What determines entosis versus apoptosis choice at the receptor level was not defined","Mechanism of caspase-8 scaffolding for entosis unresolved"]},{"year":2021,"claim":"An IFNγ-NK-astrocyte axis placed TRAIL within a microbiome-licensed neuroimmune circuit that restrains CNS inflammation by killing T cells via DR5.","evidence":"Flow cytometry screening, scRNA-seq, in vivo CRISPR-Cas9 cell-specific perturbation, and T cell apoptosis assays in mice","pmids":["33408417"],"confidence":"High","gaps":["The transcriptional repressors that silence astrocytic TRAIL during inflammation were not fully defined","Human relevance of this circuit not established"]},{"year":null,"claim":"How receptor compartmentalization, glycosylation, and adaptor/regulator stoichiometry collectively dictate the choice among apoptosis, necroptosis, entosis, and cytoprotective autophagy downstream of TRAIL remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model integrating the TRAF2/RIPK1, PRMT5, and PARP1-HMGB1 resistance nodes","The structural determinants distinguishing DR4 from DR5 signaling outputs are not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,7,9]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[8,15,16]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[15]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,1,12,14]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[3,6,11]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[10,17]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,5]}],"complexes":["DISC (death-inducing signaling complex)"],"partners":["TNFRSF10A","TNFRSF10B","FADD","PRMT5","TRAF2","RIPK1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P50591","full_name":"Tumor necrosis factor ligand superfamily member 10","aliases":["Apo-2 ligand","Apo-2L","TNF-related apoptosis-inducing ligand","Protein TRAIL"],"length_aa":281,"mass_kda":32.5,"function":"Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG (PubMed:10549288, PubMed:26457518). Induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis","subcellular_location":"Cell membrane; Secreted","url":"https://www.uniprot.org/uniprotkb/P50591/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TNFSF10","classification":"Not Classified","n_dependent_lines":18,"n_total_lines":1208,"dependency_fraction":0.014900662251655629},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TNFSF10","total_profiled":1310},"omim":[{"mim_id":"617464","title":"UNC5 FAMILY C-TERMINAL-LIKE PROTEIN; UNC5CL","url":"https://www.omim.org/entry/617464"},{"mim_id":"617078","title":"DEATH EFFECTOR DOMAIN-CONTAINING PROTEIN 2; DEDD2","url":"https://www.omim.org/entry/617078"},{"mim_id":"616147","title":"CYCLIN-DEPENDENT KINASE 15; CDK15","url":"https://www.omim.org/entry/616147"},{"mim_id":"616068","title":"HOXA CLUSTER ANTISENSE RNA 2, NONCODING; HOXAAS2","url":"https://www.omim.org/entry/616068"},{"mim_id":"615741","title":"DAP3-BINDING CELL DEATH ENHANCER 1; DELE1","url":"https://www.omim.org/entry/615741"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TNFSF10"},"hgnc":{"alias_symbol":["TRAIL","Apo-2L","TL2","CD253","TANCR"],"prev_symbol":[]},"alphafold":{"accession":"P50591","domains":[{"cath_id":"2.60.120.40","chopping":"122-278","consensus_level":"high","plddt":89.5218,"start":122,"end":278},{"cath_id":"1.20.1070","chopping":"23-56_76-88","consensus_level":"medium","plddt":84.2866,"start":23,"end":88}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P50591","model_url":"https://alphafold.ebi.ac.uk/files/AF-P50591-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P50591-F1-predicted_aligned_error_v6.png","plddt_mean":81.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TNFSF10","jax_strain_url":"https://www.jax.org/strain/search?query=TNFSF10"},"sequence":{"accession":"P50591","fasta_url":"https://rest.uniprot.org/uniprotkb/P50591.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P50591/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P50591"}},"corpus_meta":[{"pmid":"9082980","id":"PMC_9082980","title":"The receptor for the cytotoxic ligand TRAIL.","date":"1997","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9082980","citation_count":1490,"is_preprint":false},{"pmid":"9311998","id":"PMC_9311998","title":"TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.","date":"1997","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9311998","citation_count":969,"is_preprint":false},{"pmid":"12655296","id":"PMC_12655296","title":"Apo2L/TRAIL and its death and decoy receptors.","date":"2003","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/12655296","citation_count":711,"is_preprint":false},{"pmid":"24948009","id":"PMC_24948009","title":"Getting TRAIL back on track for cancer therapy.","date":"2014","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/24948009","citation_count":396,"is_preprint":false},{"pmid":"17403612","id":"PMC_17403612","title":"TRAIL signalling: decisions between life and death.","date":"2007","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/17403612","citation_count":378,"is_preprint":false},{"pmid":"33408417","id":"PMC_33408417","title":"Gut-licensed IFNγ+ NK cells drive LAMP1+TRAIL+ anti-inflammatory astrocytes.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/33408417","citation_count":271,"is_preprint":false},{"pmid":"19476510","id":"PMC_19476510","title":"Following TRAIL's path in the immune system.","date":"2009","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19476510","citation_count":240,"is_preprint":false},{"pmid":"11774036","id":"PMC_11774036","title":"TRAIL/Apo-2L: mechanisms and clinical applications in cancer.","date":"2001","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/11774036","citation_count":236,"is_preprint":false},{"pmid":"19117685","id":"PMC_19117685","title":"TRAIL receptor signalling and modulation: Are we on the right TRAIL?","date":"2008","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19117685","citation_count":230,"is_preprint":false},{"pmid":"29541897","id":"PMC_29541897","title":"Developing TRAIL/TRAIL death receptor-based cancer therapies.","date":"2018","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/29541897","citation_count":209,"is_preprint":false},{"pmid":"15504243","id":"PMC_15504243","title":"TRAIL and its receptors as targets for cancer therapy.","date":"2004","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/15504243","citation_count":208,"is_preprint":false},{"pmid":"12628743","id":"PMC_12628743","title":"TRAIL-induced signalling and apoptosis.","date":"2003","source":"Toxicology letters","url":"https://pubmed.ncbi.nlm.nih.gov/12628743","citation_count":194,"is_preprint":false},{"pmid":"25883904","id":"PMC_25883904","title":"Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells.","date":"2015","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25883904","citation_count":184,"is_preprint":false},{"pmid":"18329793","id":"PMC_18329793","title":"TRAIL and cancer therapy.","date":"2008","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/18329793","citation_count":151,"is_preprint":false},{"pmid":"16884904","id":"PMC_16884904","title":"The clinical trail of TRAIL.","date":"2006","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/16884904","citation_count":148,"is_preprint":false},{"pmid":"9382834","id":"PMC_9382834","title":"Cell death: TRAIL and its receptors.","date":"1997","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/9382834","citation_count":140,"is_preprint":false},{"pmid":"15987601","id":"PMC_15987601","title":"Expression of TRAIL and TRAIL receptors in normal and malignant tissues.","date":"2005","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15987601","citation_count":138,"is_preprint":false},{"pmid":"16357130","id":"PMC_16357130","title":"TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16357130","citation_count":137,"is_preprint":false},{"pmid":"10229846","id":"PMC_10229846","title":"TRAIL (Apo-2L) and TRAIL receptors in human placentas: implications for immune privilege.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10229846","citation_count":137,"is_preprint":false},{"pmid":"23051914","id":"PMC_23051914","title":"Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2- and RIPK1/RIP1-mediated MAPK8/JNK activation.","date":"2012","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/23051914","citation_count":132,"is_preprint":false},{"pmid":"20819019","id":"PMC_20819019","title":"TRAIL receptor signaling and therapeutics.","date":"2010","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/20819019","citation_count":126,"is_preprint":false},{"pmid":"16750931","id":"PMC_16750931","title":"The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology.","date":"2006","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/16750931","citation_count":118,"is_preprint":false},{"pmid":"17485341","id":"PMC_17485341","title":"TRAIL: a multifunctional cytokine.","date":"2007","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/17485341","citation_count":107,"is_preprint":false},{"pmid":"15916713","id":"PMC_15916713","title":"Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells.","date":"2005","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15916713","citation_count":99,"is_preprint":false},{"pmid":"18381408","id":"PMC_18381408","title":"Mcl-1: a gateway to TRAIL sensitization.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18381408","citation_count":98,"is_preprint":false},{"pmid":"19106633","id":"PMC_19106633","title":"TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death.","date":"2008","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/19106633","citation_count":92,"is_preprint":false},{"pmid":"31561055","id":"PMC_31561055","title":"The TRAIL to cancer therapy: Hindrances and potential solutions.","date":"2019","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/31561055","citation_count":88,"is_preprint":false},{"pmid":"37345089","id":"PMC_37345089","title":"The Role of TRAIL in Apoptosis and Immunosurveillance in Cancer.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/37345089","citation_count":85,"is_preprint":false},{"pmid":"19760076","id":"PMC_19760076","title":"TRAIL and other TRAIL receptor agonists as novel cancer therapeutics.","date":"2009","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/19760076","citation_count":81,"is_preprint":false},{"pmid":"28186505","id":"PMC_28186505","title":"N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death.","date":"2017","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/28186505","citation_count":79,"is_preprint":false},{"pmid":"12486874","id":"PMC_12486874","title":"On the TRAIL to apoptosis.","date":"2002","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/12486874","citation_count":77,"is_preprint":false},{"pmid":"22892844","id":"PMC_22892844","title":"Regulation of the human TRAIL gene.","date":"2012","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/22892844","citation_count":75,"is_preprint":false},{"pmid":"10198234","id":"PMC_10198234","title":"Expression of TRAIL and its receptors in human brain tumors.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10198234","citation_count":75,"is_preprint":false},{"pmid":"30943823","id":"PMC_30943823","title":"Nutrition for Ultramarathon Running: Trail, Track, and Road.","date":"2019","source":"International journal of sport nutrition and exercise metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30943823","citation_count":74,"is_preprint":false},{"pmid":"25299769","id":"PMC_25299769","title":"TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis.","date":"2014","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/25299769","citation_count":71,"is_preprint":false},{"pmid":"25472798","id":"PMC_25472798","title":"Neutralization of TNFSF10 ameliorates functional outcome in a murine model of Alzheimer's disease.","date":"2014","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25472798","citation_count":70,"is_preprint":false},{"pmid":"19275567","id":"PMC_19275567","title":"TRAIL gene therapy: from preclinical development to clinical application.","date":"2009","source":"Current gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/19275567","citation_count":67,"is_preprint":false},{"pmid":"32682900","id":"PMC_32682900","title":"TRAIL therapy and prospective developments for cancer treatment.","date":"2020","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/32682900","citation_count":65,"is_preprint":false},{"pmid":"19854352","id":"PMC_19854352","title":"The TRAIL to targeted therapy of breast cancer.","date":"2009","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19854352","citation_count":65,"is_preprint":false},{"pmid":"19372584","id":"PMC_19372584","title":"PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation.","date":"2009","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/19372584","citation_count":65,"is_preprint":false},{"pmid":"24909167","id":"PMC_24909167","title":"TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24909167","citation_count":64,"is_preprint":false},{"pmid":"17438088","id":"PMC_17438088","title":"Targeting TRAIL agonistic receptors for cancer therapy.","date":"2007","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17438088","citation_count":62,"is_preprint":false},{"pmid":"18061141","id":"PMC_18061141","title":"Expression, regulation and function of trail in atherosclerosis.","date":"2007","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18061141","citation_count":61,"is_preprint":false},{"pmid":"11991679","id":"PMC_11991679","title":"Potential and caveats of TRAIL in cancer therapy.","date":"2001","source":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/11991679","citation_count":60,"is_preprint":false},{"pmid":"31333662","id":"PMC_31333662","title":"Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling: Implications for TRAIL Receptor Targeted Therapy.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31333662","citation_count":56,"is_preprint":false},{"pmid":"27740879","id":"PMC_27740879","title":"Hepatitis B virus-triggered autophagy targets TNFRSF10B/death receptor 5 for degradation to limit TNFSF10/TRAIL response.","date":"2016","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/27740879","citation_count":54,"is_preprint":false},{"pmid":"15110174","id":"PMC_15110174","title":"TRAIL and NFkappaB signaling--a complex relationship.","date":"2004","source":"Vitamins and hormones","url":"https://pubmed.ncbi.nlm.nih.gov/15110174","citation_count":54,"is_preprint":false},{"pmid":"31444476","id":"PMC_31444476","title":"TRAIL-based gene delivery and therapeutic strategies.","date":"2019","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/31444476","citation_count":53,"is_preprint":false},{"pmid":"15110178","id":"PMC_15110178","title":"FLIP protein and TRAIL-induced apoptosis.","date":"2004","source":"Vitamins and hormones","url":"https://pubmed.ncbi.nlm.nih.gov/15110178","citation_count":53,"is_preprint":false},{"pmid":"25165876","id":"PMC_25165876","title":"Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2.","date":"2014","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/25165876","citation_count":53,"is_preprint":false},{"pmid":"25703843","id":"PMC_25703843","title":"On the organ trail: insights into organ regeneration in the planarian.","date":"2015","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/25703843","citation_count":53,"is_preprint":false},{"pmid":"11139287","id":"PMC_11139287","title":"Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan.","date":"2000","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/11139287","citation_count":53,"is_preprint":false},{"pmid":"17240413","id":"PMC_17240413","title":"TRAIL death receptors and cancer therapeutics.","date":"2006","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17240413","citation_count":53,"is_preprint":false},{"pmid":"25607248","id":"PMC_25607248","title":"Poly-ADP-ribosylation of HMGB1 regulates TNFSF10/TRAIL resistance through autophagy.","date":"2015","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/25607248","citation_count":51,"is_preprint":false},{"pmid":"23203129","id":"PMC_23203129","title":"Targeting death receptor TRAIL-R2 by chalcones for TRAIL-induced apoptosis in cancer cells.","date":"2012","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23203129","citation_count":49,"is_preprint":false},{"pmid":"17485268","id":"PMC_17485268","title":"The role of TRAIL/TRAIL receptors in central nervous system pathology.","date":"2007","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/17485268","citation_count":48,"is_preprint":false},{"pmid":"32084560","id":"PMC_32084560","title":"TRAIL in oncology: From recombinant TRAIL to nano- and self-targeted TRAIL-based therapies.","date":"2020","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/32084560","citation_count":47,"is_preprint":false},{"pmid":"22407575","id":"PMC_22407575","title":"Resistance to TRAIL and how to surmount it.","date":"2012","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/22407575","citation_count":47,"is_preprint":false},{"pmid":"14508083","id":"PMC_14508083","title":"TRAIL and anti-tumor responses.","date":"2003","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/14508083","citation_count":47,"is_preprint":false},{"pmid":"24272484","id":"PMC_24272484","title":"Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24272484","citation_count":44,"is_preprint":false},{"pmid":"21220186","id":"PMC_21220186","title":"Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL.","date":"2011","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/21220186","citation_count":44,"is_preprint":false},{"pmid":"16224489","id":"PMC_16224489","title":"On the TRAIL of a new therapy for leukemia.","date":"2005","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/16224489","citation_count":44,"is_preprint":false},{"pmid":"17172650","id":"PMC_17172650","title":"Following the TRAIL to apoptosis.","date":"2006","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/17172650","citation_count":42,"is_preprint":false},{"pmid":"17786298","id":"PMC_17786298","title":"The NO TRAIL to YES TRAIL in cancer therapy (review).","date":"2007","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17786298","citation_count":41,"is_preprint":false},{"pmid":"33401962","id":"PMC_33401962","title":"Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy.","date":"2021","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/33401962","citation_count":39,"is_preprint":false},{"pmid":"17981533","id":"PMC_17981533","title":"TRAIL and osteoprotegerin: a role in endothelial physiopathology?","date":"2008","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/17981533","citation_count":39,"is_preprint":false},{"pmid":"20336667","id":"PMC_20336667","title":"TRAIL/TRAIL-R in hematologic malignancies.","date":"2010","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20336667","citation_count":38,"is_preprint":false},{"pmid":"31297857","id":"PMC_31297857","title":"Upregulation of long noncoding TNFSF10 contributes to osteoarthritis progression through the miR-376-3p/FGFR1 axis.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31297857","citation_count":38,"is_preprint":false},{"pmid":"28914952","id":"PMC_28914952","title":"Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy.","date":"2017","source":"Nanoscale","url":"https://pubmed.ncbi.nlm.nih.gov/28914952","citation_count":38,"is_preprint":false},{"pmid":"34611142","id":"PMC_34611142","title":"Targeting the miRNA-155/TNFSF10 network restrains inflammatory response in the retina in a mouse model of Alzheimer's disease.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34611142","citation_count":38,"is_preprint":false},{"pmid":"19540014","id":"PMC_19540014","title":"Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis.","date":"2009","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/19540014","citation_count":38,"is_preprint":false},{"pmid":"16922616","id":"PMC_16922616","title":"TRAIL receptor-targeted therapy.","date":"2006","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16922616","citation_count":37,"is_preprint":false},{"pmid":"29195774","id":"PMC_29195774","title":"Paving TRAIL's Path with Ubiquitin.","date":"2017","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29195774","citation_count":37,"is_preprint":false},{"pmid":"10960444","id":"PMC_10960444","title":"Expression and antitumor effects of TRAIL in human cholangiocarcinoma.","date":"2000","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/10960444","citation_count":37,"is_preprint":false},{"pmid":"18625341","id":"PMC_18625341","title":"Targeting TRAIL death receptors.","date":"2008","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18625341","citation_count":37,"is_preprint":false},{"pmid":"27403809","id":"PMC_27403809","title":"Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27403809","citation_count":36,"is_preprint":false},{"pmid":"31083589","id":"PMC_31083589","title":"Countering TRAIL Resistance in Melanoma.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31083589","citation_count":35,"is_preprint":false},{"pmid":"23091198","id":"PMC_23091198","title":"TRAIL: not just for tumors anymore?","date":"2012","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23091198","citation_count":34,"is_preprint":false},{"pmid":"34546352","id":"PMC_34546352","title":"TRAIL signaling promotes entosis in colorectal cancer.","date":"2021","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/34546352","citation_count":34,"is_preprint":false},{"pmid":"15110188","id":"PMC_15110188","title":"Regulation of sensitivity to TRAIL by the PTEN tumor suppressor.","date":"2004","source":"Vitamins and hormones","url":"https://pubmed.ncbi.nlm.nih.gov/15110188","citation_count":34,"is_preprint":false},{"pmid":"36629496","id":"PMC_36629496","title":"Therapeutic targeting of TRAIL death receptors.","date":"2023","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/36629496","citation_count":33,"is_preprint":false},{"pmid":"23813857","id":"PMC_23813857","title":"The TRAIL of oncogenes to apoptosis.","date":"2013","source":"BioFactors (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23813857","citation_count":32,"is_preprint":false},{"pmid":"33919846","id":"PMC_33919846","title":"Overcoming TRAIL Resistance for Glioblastoma Treatment.","date":"2021","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/33919846","citation_count":31,"is_preprint":false},{"pmid":"34933177","id":"PMC_34933177","title":"Cardioprotection of M2 macrophages-derived exosomal microRNA-24-3p/Tnfsf10 axis against myocardial injury after sepsis.","date":"2021","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34933177","citation_count":31,"is_preprint":false},{"pmid":"32245106","id":"PMC_32245106","title":"On the TRAIL of Better Therapies: Understanding TNFRSF Structure-Function.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32245106","citation_count":31,"is_preprint":false},{"pmid":"15539085","id":"PMC_15539085","title":"Expression of TNF-related apoptosis-inducing ligand (TRAIL) in megakaryocytes and platelets.","date":"2004","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/15539085","citation_count":31,"is_preprint":false},{"pmid":"10931534","id":"PMC_10931534","title":"Induction of apoptosis in glioma cell lines by TRAIL/Apo-2l.","date":"2000","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/10931534","citation_count":31,"is_preprint":false},{"pmid":"17127445","id":"PMC_17127445","title":"Apo2L/TRAIL and immune regulation.","date":"2007","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/17127445","citation_count":30,"is_preprint":false},{"pmid":"20712573","id":"PMC_20712573","title":"TRAIL: a sword for killing tumors.","date":"2010","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20712573","citation_count":30,"is_preprint":false},{"pmid":"18469516","id":"PMC_18469516","title":"TRAIL death receptors as tumor suppressors and drug targets.","date":"2008","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/18469516","citation_count":30,"is_preprint":false},{"pmid":"30740527","id":"PMC_30740527","title":"TRAIL pathway targeting therapeutics.","date":"2018","source":"Expert review of precision medicine and drug development","url":"https://pubmed.ncbi.nlm.nih.gov/30740527","citation_count":28,"is_preprint":false},{"pmid":"15110189","id":"PMC_15110189","title":"TRAIL and malignant glioma.","date":"2004","source":"Vitamins and hormones","url":"https://pubmed.ncbi.nlm.nih.gov/15110189","citation_count":28,"is_preprint":false},{"pmid":"15110182","id":"PMC_15110182","title":"Modulation of TRAIL signaling for cancer therapy.","date":"2004","source":"Vitamins and hormones","url":"https://pubmed.ncbi.nlm.nih.gov/15110182","citation_count":28,"is_preprint":false},{"pmid":"27528614","id":"PMC_27528614","title":"Differences and Similarities in TRAIL- and Tumor Necrosis Factor-Mediated Necroptotic Signaling in Cancer Cells.","date":"2016","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27528614","citation_count":27,"is_preprint":false},{"pmid":"12761581","id":"PMC_12761581","title":"A caspase-8-independent component in TRAIL/Apo-2L-induced cell death in human rhabdomyosarcoma cells.","date":"2003","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/12761581","citation_count":27,"is_preprint":false},{"pmid":"27989503","id":"PMC_27989503","title":"A Purinergic Trail for Metastases.","date":"2016","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27989503","citation_count":26,"is_preprint":false},{"pmid":"30101145","id":"PMC_30101145","title":"Divergent Roles for TRAIL in Lung Diseases.","date":"2018","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30101145","citation_count":26,"is_preprint":false},{"pmid":"19077262","id":"PMC_19077262","title":"TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma.","date":"2008","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/19077262","citation_count":26,"is_preprint":false},{"pmid":"19954896","id":"PMC_19954896","title":"Differential expression of the TRAIL/TRAIL-receptor system in patients with inflammatory bowel disease.","date":"2009","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/19954896","citation_count":26,"is_preprint":false},{"pmid":"15828026","id":"PMC_15828026","title":"Functional expression of TRAIL and TRAIL-R2 during human megakaryocytic development.","date":"2005","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15828026","citation_count":21,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43335,"output_tokens":5050,"usd":0.102877,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13478,"output_tokens":4781,"usd":0.093457,"stage2_stop_reason":"end_turn"},"total_usd":0.196334,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"TRAIL (TNFSF10) binds to DR4 (death receptor-4), an undescribed TNF-receptor family member containing a cytoplasmic death domain that engages the cell apoptotic apparatus. DR4 could not use FADD to transmit the death signal, unlike Fas, TNFR-1, and DR3, indicating distinct proximal signaling machinery.\",\n      \"method\": \"Receptor identification via homology/database searching, functional death domain characterization, FADD signaling assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — foundational receptor identification with functional characterization, widely replicated across the field\",\n      \"pmids\": [\"9082980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TRAIL binds a second distinct receptor, TRAIL-R2, identified by ligand-based affinity purification. TRAIL-R2 contains two extracellular cysteine-rich repeats and a cytoplasmic death domain, mediates caspase-dependent apoptosis, and uses the intracellular adaptor molecule FADD/MORT1 (in contrast to TRAIL-R1).\",\n      \"method\": \"Ligand-based affinity purification, molecular cloning, TRAIL-R2-Fc fusion protein inhibition assay, FADD interaction characterization\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution via affinity purification, cloning, functional inhibition assay, replicated across labs\",\n      \"pmids\": [\"9311998\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TRAIL (TNFSF10) is a transcriptional target of p53. Two p53 DNA-binding sites exist in the human TNFSF10 promoter at 346 and 625 bp upstream of the transcription start site. Ad-p53 induced TRAIL mRNA and protein in HCT116 p53-/- cells; TRAIL promoter reporter assay confirmed p53-dependent transactivation. siRNA knockdown of TNFSF10 suppressed caspase-3/7 activity after adriamycin treatment.\",\n      \"method\": \"Adenoviral p53 overexpression, TRAIL promoter-luciferase reporter assay, siRNA knockdown, caspase activity assay\",\n      \"journal\": \"Cancer biology & therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — promoter reporter assay with defined binding sites, loss-of-function siRNA, multiple orthogonal methods in one study\",\n      \"pmids\": [\"19106633\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TRAIL-induced autophagy is cytoprotective and attenuates TRAIL-induced apoptosis. The mechanism involves TRAF2- and RIPK1-mediated MAPK8/JNK activation, which promotes BCL2L1/Bcl-xL degradation and dissolution of the BCL2L1-BECN1 complex. MAPK8 blockade, but not NFκB blockade, inhibited TRAIL-induced autophagy; knockdown of TRAF2 or RIPK1 suppressed MAPK8 activation and autophagy. Suppressing autophagy increased TRAIL DISC formation.\",\n      \"method\": \"Pharmacological inhibitors, siRNA knockdown of BECN1, ATG7, TRAF2, RIPK1, MAPK8; DISC formation assay; Western blot\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal siRNA and pharmacological interventions, DISC formation readout, single lab\",\n      \"pmids\": [\"23051914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PRMT5 (protein arginine methyltransferase 5) is a novel TRAIL receptor-binding protein that selectively interacts with DR4 and DR5 but not with TNFR1 or Fas. PRMT5 promotes TRAIL-induced IKK and NF-κB activation, contributing to TRAIL resistance. PRMT5 gene silencing sensitized cancer cells to TRAIL without affecting TRAIL resistance in nontransformed cells; this sensitization was rescued by ectopic active IKKβ.\",\n      \"method\": \"Proteomic screening, Co-immunoprecipitation, siRNA knockdown, IKK/NF-κB activity assay, ectopic IKKβ rescue\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal interaction confirmed by proteomic screen and Co-IP, functional rescue experiment, single lab\",\n      \"pmids\": [\"19372584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TRAF2 is a negative regulator of TRAIL-induced apoptosis and necroptosis. TRAF2 knockdown sensitized keratinocytes and HeLa cells to TRAIL-induced caspase-dependent apoptosis; in RIP3-expressing cells, TRAF2 KD additionally sensitized cells to TRAIL-induced necroptosis. TRAIL-induced necroptosis did not depend on autocrine TNF/TNFR signaling.\",\n      \"method\": \"siRNA knockdown of TRAF2, pan-caspase inhibition (zVAD-fmk), RIP1 inhibitor (necrostatin-1), RIP3-transfected HeLa cells, TWEAK priming to deplete cytosolic TRAF2, TNFR2-Fc/anti-TNFα blocking\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cell models, pharmacological + genetic perturbations, orthogonal inhibitors confirming both apoptotic and necroptotic roles\",\n      \"pmids\": [\"25299769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PARP1-mediated poly-ADP-ribosylation of HMGB1 is required for TRAIL-induced HMGB1 cytoplasmic translocation and subsequent HMGB1-BECN1 complex formation, which drives cytoprotective autophagy and TRAIL resistance. Pharmacological PARP1 inhibition or PARP1 knockdown suppressed TRAIL-induced HMGB1 translocation, reduced autophagy, increased apoptosis, and enhanced TRAIL anticancer activity.\",\n      \"method\": \"PARP1 inhibitors, siRNA knockdown of PARP1, HMGB1 localization assay, Co-immunoprecipitation of HMGB1-BECN1, in vitro and in vivo (subcutaneous tumor) models\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, genetic and pharmacological inhibition, in vivo validation, single lab\",\n      \"pmids\": [\"25607248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TRAIL-R1-selective and TRAIL-R2-selective mutants of TRAIL were synthesized. Primary CLL and mantle cell lymphoma cells signal apoptosis almost exclusively through TRAIL-R1, demonstrated by selective receptor binding and DISC formation assays using receptor-specific TRAIL mutants.\",\n      \"method\": \"Synthesis of receptor-selective TRAIL mutants, selective receptor binding assay, DISC formation assay, primary patient cell apoptosis assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — receptor-selective mutants with direct binding and DISC formation validation, primary patient cells, multiple methods\",\n      \"pmids\": [\"16357130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"N-linked glycosylation of TRAIL-R1 (and mouse TRAIL-R) promotes TRAIL-induced apoptosis by enhancing receptor aggregation and DISC formation, but does not affect TRAIL-binding affinity. N-glyc-deficient mutants of TRAIL-R1 showed reduced apoptotic signaling, lower receptor aggregation, and reduced DISC formation. Additionally, N-glycosylation of TRAIL-R1 reduces binding affinity for CMV UL141 protein, which restricts TRAIL-R1 surface expression.\",\n      \"method\": \"N-glycosylation-defective mutagenesis, apoptosis assays, DISC formation assay, receptor aggregation analysis, TRAIL binding affinity measurement, UL141 binding affinity assay\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis with multiple functional readouts (DISC, aggregation, binding, viral evasion), single lab with orthogonal methods\",\n      \"pmids\": [\"28186505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Concomitant binding of non-tagged Apo2L/TRAIL and the TRAIL-R2-specific antibody AMG655 to TRAIL-R2 synergistically enhances DISC formation and cancer cell killing. The increased killing was due to enhanced TRAIL-R2 DISC formation enabled by simultaneous ligand and antibody engagement.\",\n      \"method\": \"DISC formation assay, apoptosis assay in cancer cell lines and primary ovarian cancer cells, combination treatment with non-tagged TRAIL + AMG655\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — DISC formation mechanistic assay, validated in primary cells, single lab with two orthogonal methods\",\n      \"pmids\": [\"24909167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRAIL expression in astrocytes (LAMP1+TRAIL+ subset) is driven by IFNγ produced by meningeal NK cells (which are licensed by the gut microbiome). These astrocytes limit CNS inflammation by inducing T cell apoptosis via TRAIL-DR5 signaling. TRAIL expression in astrocytes is repressed by molecules from T cells and microglia during inflammation.\",\n      \"method\": \"High-throughput flow cytometry screening, single-cell RNA sequencing, CRISPR-Cas9-based cell-specific in vivo genetic perturbations in mice, T cell apoptosis assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR-Cas9 genetic perturbation in vivo, multiple orthogonal methods, published in high-tier journal with rigorous validation\",\n      \"pmids\": [\"33408417\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Hepatitis B virus X protein (HBx) promotes autophagy-mediated lysosomal degradation of TRAIL death receptor TNFRSF10B/DR5, restricting TRAIL-induced apoptosis in virus-infected hepatocytes. HBx directly interacts with TNFRSF10B and recruits it to phagophores via an autophagy receptor-like mechanism, promoting association of TNFRSF10B with LC3B.\",\n      \"method\": \"Immunoprecipitation, GST affinity isolation, LC3B knockdown, pharmacological autophagy inhibition, tandem-fluorescence-tagged LC3B microscopy, immunoblotting of patient liver tissues\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — GST pulldown and Co-IP, genetic and pharmacological autophagy inhibition, patient tissue validation, multiple orthogonal methods\",\n      \"pmids\": [\"27740879\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRAIL signaling activates entosis (cell-in-cell formation) in colon cancer cells via DR4 and DR5 receptors. Entosis induction diverges from apoptosis at caspase-8: structural presence of caspase-8 is sufficient for entosis but not apoptosis. Bax/Bak knockout or caspase inhibition also inhibits entotic cell death. CIC structures in colorectal tumors associate with TRAIL signaling and adverse prognosis.\",\n      \"method\": \"TRAIL receptor KO (DR4/DR5), caspase-8 structural mutants, Bax/Bak double knockout, caspase inhibition, live imaging, colorectal tumor analysis\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO of receptors and downstream components, structural mutant rescue, mechanistic bifurcation between apoptosis and entosis established\",\n      \"pmids\": [\"34546352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"In rhabdomyosarcoma cells, TRAIL ligation induces DISC formation with recruitment of FADD and procaspase-8 in both sensitive and resistant cells. TRAIL-induced apoptosis has a caspase-8-independent component: dominant-negative caspase-8 only partially inhibited TRAIL-induced apoptosis and did not inhibit Bid cleavage or Bax activation, while dominant-negative FADD completely abolished TRAIL-induced cell death. Inhibition of sphingosine kinase completely protected cells from TRAIL-induced apoptosis, implicating the sphingomyelin cycle.\",\n      \"method\": \"DISC formation assay, dominant-negative FADD/caspase-8 overexpression, Bcl-2/Bcl-xL overexpression, Bax activation assay, sphingosine kinase inhibition\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dominant-negative constructs and rescue experiments, DISC assay, multiple pathway dissection methods, single lab\",\n      \"pmids\": [\"12761581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TRAIL-mediated necroptosis requires acid and neutral sphingomyelinases, mitochondrial serine protease HtrA2/Omi, Atg5, and vacuolar H(+)-ATPase, and is independent of PARP-1. TRAIL-mediated necroptosis differs from TNF-mediated necroptosis in not requiring UCH-L1 or Atg16L1, and does not require receptor internalization or endosome-lysosome acidification. Bcl-XL overexpression inhibited TRAIL- but not TNF-mediated necroptosis in Colo357 cells.\",\n      \"method\": \"Pharmacological inhibitors, genetic knockdown, Bcl-2/Bcl-XL overexpression, receptor internalization assay, endosome acidification inhibition\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological and genetic perturbations, comparative TNF vs TRAIL necroptosis, single lab\",\n      \"pmids\": [\"27528614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"TRAIL expression in megakaryocytes is induced upon megakaryocytic differentiation via increased transcriptional activity of the TRAIL promoter, indicating lineage-specific transcriptional regulation. Activated platelets express both membrane-bound and soluble TRAIL, synthesized during megakaryocyte differentiation.\",\n      \"method\": \"Immunoprecipitation, ELISA, flow cytometry, RT-PCR, TRAIL promoter/reporter transient transfection assays, TRAIL-dependent cytotoxicity assays\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter assay with multiple protein-level validations, single lab\",\n      \"pmids\": [\"15539085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"During human megakaryocytic development, surface TRAIL and TRAIL-R2 are co-expressed starting from early differentiation. Recombinant TRAIL increases apoptosis of CD34+/CD41(dim) megakaryoblasts and decreases total megakaryocytic output. Blockade of endogenous TRAIL-TRAIL-R2 interaction by TRAIL-R2-Fc chimera increases total megakaryocytic cell count, demonstrating an autocrine/paracrine regulatory role of endogenous TRAIL in megakaryocytopoiesis.\",\n      \"method\": \"Flow cytometry of surface receptors, recombinant TRAIL treatment, TRAIL-R2-Fc chimera blockade, primary CD34+ cell culture differentiation assay\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional ligand-receptor blockade with defined cellular readout, primary human cells, single lab\",\n      \"pmids\": [\"15828026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TRAIL and all four TRAIL receptors (DR4, DR5, DcR1, DcR2) are expressed in human placentas by Northern blotting. TRAIL protein is prominent in syncytiotrophoblast and Hofbauer cells by immunohistochemistry. Trophoblast cell lines are resistant to rTRAIL killing while macrophage lines are partially susceptible. IFN-γ increases TRAIL mRNA in both lineages but only increases DR4 mRNA in macrophages. These findings support a role for the TRAIL/TRAIL-R system in placental immune privilege.\",\n      \"method\": \"Northern blotting, immunohistochemistry, cytotoxicity assays, IFN-γ stimulation, cell lineage-specific receptor expression analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (Northern, IHC, functional cytotoxicity), primary tissue and cell lines, single lab\",\n      \"pmids\": [\"10229846\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TNFSF10/TRAIL is a TNF superfamily member that, as a trimer, binds death receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2)—each containing cytoplasmic death domains—to recruit FADD and procaspase-8 into a death-inducing signaling complex (DISC), initiating caspase-dependent apoptosis; DR4 signals independently of FADD while DR5 uses FADD/MORT1, TRAIL-R1 is regulated by N-linked glycosylation that promotes DISC formation, TRAIL expression is transactivated by p53 and by IFNγ in immune cells including NK cells and astrocytes, and non-apoptotic TRAIL outcomes (NF-κB activation, autophagy, entosis, necroptosis) are modulated by TRAF2, RIPK1/MAPK8, PARP1-HMGB1, PRMT5, and receptor compartmentalization.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TNFSF10 (TRAIL) is a TNF-superfamily death ligand that engages cell-surface death receptors to trigger caspase-dependent apoptosis and a broader set of regulated cell-death and inflammatory programs [#0, #1]. It binds two distinct death-domain-containing receptors: DR4/TRAIL-R1, which initially appeared to transmit death signals through machinery distinct from FADD, and TRAIL-R2/DR5, which recruits the adaptor FADD/MORT1 to assemble a death-inducing signaling complex (DISC) with procaspase-8 [#0, #1, #13]. DISC assembly and apoptotic output are tunable: N-linked glycosylation of TRAIL-R1 enhances receptor aggregation and DISC formation without altering ligand affinity [#8], receptor-selective TRAIL variants reveal that some primary tumors signal almost exclusively through TRAIL-R1 [#7], and co-engagement of TRAIL-R2 by ligand plus the agonist antibody AMG655 synergistically amplifies DISC formation and killing [#9]. TRAIL also drives non-apoptotic outcomes through the same receptors—cytoprotective autophagy via TRAF2/RIPK1-MAPK8/JNK signaling that degrades BCL2L1 and via PARP1-dependent HMGB1-BECN1 complex formation [#3, #6], necroptosis dependent on sphingomyelinases and HtrA2/Omi [#5, #14], and entosis that diverges from apoptosis at caspase-8 [#12]—with TRAF2 and PRMT5 acting as negative regulators that restrain death signaling and promote NF-κB-driven resistance [#4, #5]. TRAIL expression is transcriptionally controlled: it is a direct p53 target gene through promoter binding sites that mediate chemotherapy-induced apoptosis [#2], and is induced by IFNγ in immune and tissue contexts, including IFNγ-driven astrocytes that limit CNS inflammation by inducing T-cell apoptosis through TRAIL-DR5 [#10]. Lineage-specific induction also governs roles in megakaryocyte differentiation, where autocrine TRAIL-TRAIL-R2 signaling regulates megakaryocytic output [#15, #16].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Establishing the receptors through which TRAIL signals defined how an extracellular ligand engages the intracellular apoptotic apparatus, and revealed early evidence for receptor-specific signaling logic.\",\n      \"evidence\": \"Receptor identification by homology/database searching and ligand-based affinity purification, with death-domain and FADD-signaling characterization (DR4/TRAIL-R1 and TRAIL-R2/DR5)\",\n      \"pmids\": [\"9082980\", \"9311998\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The apparent FADD-independence of DR4 versus FADD-dependence of DR5 was not reconciled at the structural level\", \"Stoichiometry of the receptor-FADD-procaspase-8 DISC was not resolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Dissecting DISC composition in sensitive versus resistant cells showed apoptotic output is not strictly caspase-8-dependent, implicating parallel pathways including sphingolipid signaling.\",\n      \"evidence\": \"DISC assay with dominant-negative FADD/caspase-8 overexpression, Bax activation assay, and sphingosine kinase inhibition in rhabdomyosarcoma cells\",\n      \"pmids\": [\"12761581\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The molecular identity of the caspase-8-independent death effector was not established\", \"Single-lab, single-tumor-type observation\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Receptor-selective TRAIL mutants demonstrated that individual tumors can depend on a single receptor, with direct therapeutic targeting implications.\",\n      \"evidence\": \"Synthesis of TRAIL-R1- and TRAIL-R2-selective mutants with selective binding and DISC formation assays in primary CLL and mantle cell lymphoma cells\",\n      \"pmids\": [\"16357130\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why these tumors favor TRAIL-R1 was not mechanistically explained\", \"Receptor preference across broader tumor types was not surveyed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identifying TNFSF10 as a direct p53 target connected the apoptotic ligand to the canonical tumor-suppressor and chemotherapy response.\",\n      \"evidence\": \"Adenoviral p53 overexpression, TRAIL promoter-luciferase reporter with mapped binding sites, siRNA knockdown, and caspase activity assays in HCT116 cells\",\n      \"pmids\": [\"19106633\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The relative contribution of p53-driven TRAIL versus other p53 apoptotic targets was not quantified\", \"In vivo relevance to tumor regression was not tested here\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery of PRMT5 as a selective death-receptor-binding protein revealed a built-in resistance mechanism coupling receptor engagement to NF-κB survival signaling.\",\n      \"evidence\": \"Proteomic screen, Co-IP showing selective DR4/DR5 (not TNFR1/Fas) binding, siRNA knockdown, and IKKβ rescue of NF-κB activity\",\n      \"pmids\": [\"19372584\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PRMT5 methyltransferase activity is required was not resolved\", \"Structural basis of selective receptor binding unknown\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Mapping a TRAF2/RIPK1-MAPK8 axis showed TRAIL induces cytoprotective autophagy that antagonizes its own DISC formation, explaining a source of resistance.\",\n      \"evidence\": \"Pharmacological inhibitors and siRNA knockdown of TRAF2, RIPK1, MAPK8, BECN1, ATG7 with DISC formation readout\",\n      \"pmids\": [\"23051914\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How autophagy physically suppresses DISC assembly was not defined\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"TRAF2 was established as a negative regulator gating both apoptosis and RIP3-dependent necroptosis downstream of TRAIL, independent of autocrine TNF.\",\n      \"evidence\": \"siRNA knockdown of TRAF2 with zVAD-fmk, necrostatin-1, RIP3 transfection, and TNF blockade across keratinocytes and HeLa cells\",\n      \"pmids\": [\"25299769\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The biochemical target through which TRAF2 restrains the DISC was not identified\", \"Generality across cell types not fully mapped\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Combining TRAIL with an agonist TRAIL-R2 antibody showed DISC formation can be cooperatively amplified, providing a route to overcome resistance.\",\n      \"evidence\": \"DISC formation and apoptosis assays with non-tagged Apo2L/TRAIL plus AMG655 in cancer cell lines and primary ovarian cancer cells\",\n      \"pmids\": [\"24909167\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The receptor cluster geometry enabling synergy was not structurally defined\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"A PARP1-HMGB1 axis was shown to drive cytoprotective autophagy and TRAIL resistance, identifying a distinct druggable resistance node.\",\n      \"evidence\": \"PARP1 inhibitors and knockdown, HMGB1 localization, HMGB1-BECN1 Co-IP, and subcutaneous tumor models\",\n      \"pmids\": [\"25607248\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How PARP1 is activated by TRAIL signaling was not established\", \"Relationship to the TRAF2/RIPK1 autophagy axis not integrated\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defining the effector requirements of TRAIL-mediated necroptosis distinguished it mechanistically from TNF necroptosis.\",\n      \"evidence\": \"Pharmacological and genetic perturbation of sphingomyelinases, HtrA2/Omi, Atg5, V-ATPase; receptor internalization and endosome acidification assays in Colo357 cells\",\n      \"pmids\": [\"27528614\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How these effectors are assembled into a death-executing module was not resolved\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Hepatitis B virus X protein was shown to degrade DR5 via selective autophagy, demonstrating viral subversion of TRAIL death signaling.\",\n      \"evidence\": \"Co-IP, GST pulldown, LC3B knockdown, autophagy inhibition, tandem-fluorescent LC3B imaging, and patient liver tissue immunoblotting\",\n      \"pmids\": [\"27740879\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether host autophagy receptors normally turn over DR5 was not addressed\", \"Generality beyond HBV-infected hepatocytes unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"N-linked glycosylation of TRAIL-R1 was shown to control apoptotic competence by promoting receptor aggregation and DISC formation independent of ligand affinity, and to mediate viral immune evasion.\",\n      \"evidence\": \"N-glycosylation-defective mutagenesis with apoptosis, DISC, receptor aggregation, ligand affinity, and CMV UL141 binding assays\",\n      \"pmids\": [\"28186505\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How glycosylation status varies across cell types to set sensitivity was not surveyed\", \"Structural basis of glycan-driven aggregation not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"TRAIL signaling was shown to trigger entosis as a caspase-8-gated alternative to apoptosis, expanding the death-modality repertoire and linking it to tumor prognosis.\",\n      \"evidence\": \"DR4/DR5 KO, caspase-8 structural mutants, Bax/Bak double KO, caspase inhibition, live imaging, and colorectal tumor analysis\",\n      \"pmids\": [\"34546352\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"What determines entosis versus apoptosis choice at the receptor level was not defined\", \"Mechanism of caspase-8 scaffolding for entosis unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"An IFNγ-NK-astrocyte axis placed TRAIL within a microbiome-licensed neuroimmune circuit that restrains CNS inflammation by killing T cells via DR5.\",\n      \"evidence\": \"Flow cytometry screening, scRNA-seq, in vivo CRISPR-Cas9 cell-specific perturbation, and T cell apoptosis assays in mice\",\n      \"pmids\": [\"33408417\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The transcriptional repressors that silence astrocytic TRAIL during inflammation were not fully defined\", \"Human relevance of this circuit not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How receptor compartmentalization, glycosylation, and adaptor/regulator stoichiometry collectively dictate the choice among apoptosis, necroptosis, entosis, and cytoprotective autophagy downstream of TRAIL remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model integrating the TRAF2/RIPK1, PRMT5, and PARP1-HMGB1 resistance nodes\", \"The structural determinants distinguishing DR4 from DR5 signaling outputs are not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 7, 9]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [8, 15, 16]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 1, 12, 14]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [3, 6, 11]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [10, 17]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 5]}\n    ],\n    \"complexes\": [\"DISC (death-inducing signaling complex)\"],\n    \"partners\": [\"TNFRSF10A\", \"TNFRSF10B\", \"FADD\", \"PRMT5\", \"TRAF2\", \"RIPK1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}